Kindlin-3 (FERMT3)

Kindlin‑3 is a hematopoietic-restricted integrin adaptor protein encoded by the FERMT3 gene, characterized by a FERM (four-point-one, ezrin, radixin, moesin) domain and a pleckstrin homology domain[1][3]. It plays an essential and non-redundant role in integrin activation, particularly for β1, β2, and β3 integrins, supporting cell adhesion, migration, and signaling, especially in platelets and leukocytes[2][3][4][5]. Kindlin‑3 is required for normal hemostasis, thrombosis prevention, immune cell trafficking, and bone resorption by osteoclasts, and is critical for vascular development[3][4]. Mutations in FERMT3 cause leukocyte adhesion deficiency type III (LAD-III) presenting with combined bleeding diathesis and immune deficiency[2][3][4]. While there are currently no direct drugs targeting Kindlin‑3, its unique structure and vital functions in integrin pathways make it a potential therapeutic target and a diagnostic biomarker for specific hematopoietic and immune disorders[2][3][4].

Other names

Fermitin family homolog 3KIND3MIG2BURP2MGC10966UNC112Ckindlin‑3MIG2-like proteinUnc-112-related protein 2Kindlin-3

Drugs that modulate integrin activation or function may alter the activity of Kindlin‑3-dependent processes, but no small-molecule or biologic agents are known to directly target Kindlin‑3